Overview
OBIO market data
Price History
OBIO price chart
Valuation & Profitability
- P/E (TTM)
- — Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
- Forward P/E
- — P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
- EPS (TTM)
- -$1.10 Diluted earnings per share over the trailing twelve months.
- Beta
- 0.54 Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
- Dividend Yield
- — Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
- Profit Margin
- -166.8% Net income divided by revenue. Comparable within a sector, less so across sectors.
- 52w range
- $2.20 – $5.42 Lowest and highest closing prices over the past 52 weeks.
- Analyst Target
- — Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.
Display-only. Refreshed once per symbol per 24 hours · market cap $267.1M · P/B 3.70 · P/S 8.16.
Company News
Piper Sandler Reiterates Overweight on Orchestra BioMed Hldgs, Raises Price Target to $10Benzinga · Aug 11, 2026, 1:16 PM
Orchestra BioMed Hldgs Q2 EPS $(0.38) Misses $(0.37) Estimate, Sales $88.000K Miss $121.400K EstimateBenzinga · Aug 10, 2026, 9:21 PM
Orchestra BioMed Joins Russell 3000® and Russell 2000® IndexesGlobenewswire Inc · Jun 29, 2026, 12:15 PM
Orchestra BioMed Included In Russell 3000 And Russell 2000 IndexesBenzinga · Jun 29, 2026, 12:10 PM
B. Riley Securities Maintains Buy on Orchestra BioMed Hldgs, Lowers Price Target to $10Benzinga · May 19, 2026, 7:45 PM